Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
<< anterior 21 a 40 de 335 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
22. Cita con resumen
Harrington M, Sigal EV. Opinion: ‘Right-to-try’ law threatens patient safety and rational drug development. STAT Daily Recap 2018:6. [Ref.ID 102467]
23.Enlace a cita original Cita con resumen
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon Ch, Harden M, Lennon N, Gabriel S, Rodig S, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21. [Ref.ID 101662]
24. Cita con resumen
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017;37:429-39. [Ref.ID 101410]
27. Cita con resumen
Margulies KB, Hernández AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kieman MS, Felker M, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, for the NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500-8. [Ref.ID 100686]
28. Cita con resumen
29. Cita con resumen
Mayor S. “Impressive results” in stem cell treatment for multiple sclerosis. BMJ 2016;353:i3269. [Ref.ID 100429]
30. Cita con resumen
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551-60. [Ref.ID 100228]
31. Cita con resumen
Rajkumar SV. Daratumumab in multiple myleoma. Lancet 2016;387:1490-2. [Ref.ID 100220]
32.Tiene citas relacionadas Cita con resumen
Eichler H-G, Hurts H, Broich K, Rasi G. Drug regulation and pricing — Can regulators influence affordability?. N Engl J Med 2016;374:1807-9. [Ref.ID 100113]
33.Tiene citas relacionadas Cita con resumen
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NMH, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52. [Ref.ID 99988]
34. Cita con resumen
Baerlocher GM, Leibundgut EO, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Röth A, Daskalakis M, Burington B, Stuart M, Synder DS. Telomerase inhibitor imeteelstat in patients with essential thrombocythemia. N Engl J Med 2015;373:920-8. [Ref.ID 99517]
35. Cita con resumen
Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2015;385:1198-205. [Ref.ID 98993]
36.Tiene citas relacionadas Cita con resumen
Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AYM, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1087-97. [Ref.ID 98985]
37. Cita con resumen
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, for the NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-65. [Ref.ID 98959]
38. Cita con resumen
Dyer O. Experimental drug that injured UK volunteers resumes in human trials. BMJ 2015;350:h1831. [Ref.ID 98941]
39.Tiene citas relacionadas Cita con resumen
Anónimo. Experimental Alzheimer’s treatment slows cognitive decline in early trial. DIA Daily 2015:23 de marzo. [Ref.ID 98868]
40. Cita con resumen
Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay J-F, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB, on behalf of the SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 2014;384:1187-95. [Ref.ID 98113]
Seleccionar todas
 
<< anterior 21 a 40 de 335 siguiente >>